Dear Sir/Madam, Please find the attached disclosure pursuant to Regulation 23(9) of SEBI (LODR) Regulations, 2015. Thanking You.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd has disclosed its related party transactions (RPTs) for the half year ended 31 March 2025, as required under SEBI LODR Regulation 23(9). The total value of related party transactions during the reporting period was Rs. 171.86 lakhs. Key transactions included purchases of goods from Ovation Remedies (Rs. 17.68 lakhs, closing balance Rs. 31.89 lakhs due), sales to Galaxy Pharmaceuticals (Rs. 22.89 lakhs, closing balance Rs. 35.04 lakhs due), and small sales/purchases with Symbiosis Pharmaceuticals Private Limited (Rs. 0.45 and Rs. 0.79 lakhs), which shares a common director. Notably, advances of Rs. 120.73 lakhs were given to Ovation Remedies and Rs. 9.32 lakhs to Symbiosis Pharmaceuticals, both remaining outstanding at period-end. Each related party has an overall approved RPT limit of Rs. 1,000 lakhs set by the audit committee, of which only a small fraction has been utilised.
For retail investors, this is a routine compliance filing, but a few points stand out: advances of around Rs. 130 lakhs remain outstanding to related parties (especially Ovation Remedies), and transactions with Symbiosis Pharmaceuticals involve a common director, which warrants attention to corporate governance. Shareholders should watch for timely recovery of these advances and clarity on the commercial terms of these deals.